|
J Biol Chem, Vol. 273, Issue 40, 25809-25817, October 2, 1998
Random Sequence Mutagenesis and Resistance to 5-Fluorouridine in
Human Thymidylate Synthases*
Daniel M.
Landis and
Lawrence A.
Loeb
From the Departments of Pathology and Biochemistry, The Joseph
Gottstein Memorial Cancer Research Laboratory, University of Washington
School of Medicine, Seattle, Washington 98195-7705
 |
ABSTRACT |
Thymidylate synthase (TS) catalyzes the
methylation of dUMP to dTMP and is the target for the widely used
chemotherapeutic agent 5-fluorouracil. We used random sequence
mutagenesis to replace 13 codons within the active site of TS and
obtain variants that are resistant to 5-fluorodeoxyuridine (5-FdUR).
The resulting random library was selected for its ability to complement
a TS-deficient Escherichia coli strain, and sequence
analysis of survivors found multiple substitutions to be tolerable
within the targeted region. An independent selection of the library was
carried out in the presence of 5-FdUR, resulting in a more limited
spectrum of mutations. One specific mutation, C199L, was observed in
more than 46% of 5-FdUR-resistant clones. A 5-FdUR-resistant triple
mutant, A197V/L198I/C199F, was purified to apparent homogeneity.
Kinetic studies with the substrate dUMP indicate that this mutant is
similar to the wild type in regards to kcat and
Km values for dUMP and the cosubstrate
CH2H4-folate. In contrast,
equilibrium binding studies with the inhibitor, FdUMP, demonstrate that
the dissociation constant (Kd) for FdUMP binding
into the ternary complex was 20-fold higher than values obtained for
the wild-type enzyme. This 5-FdUMP-resistant mutant, or others
similarly selected, is a candidate for use in gene therapy to render
susceptible normal cells resistant to the toxic effects of systemic
5-fluorouracil.
 |
INTRODUCTION |
Thymidylate synthase
(TS)1 is a 72-kDa homodimer
that catalyzes the formation of dTMP from dUMP using
CH2H4-folate as both the single carbon unit
source and the reductant. Thymidylate synthase is a central enzyme in
DNA biosynthesis as it provides the only de novo source of
dTMP. Inhibition of TS in mammalian cells results in depletion of
cellular thymidylate, inhibition of DNA synthesis, and ultimately
thymine-less death (1-3). In addition, TS activity is greatest in
rapidly proliferating cells and is preferentially expressed at the
onset of S phase (4). For these reasons, TS has been a key target for
chemotherapeutic agents (5, 6).
The crystal structures of the human, Escherichia coli, and
Lactobacillus casei TS have been solved and share multiple
structural features (7-9). The enzyme is a symmetric dimer of
structurally identical subunits. Deep within the active site cavity,
three arginine residues and one serine residue coordinate the bound phosphate. Two of these arginine residues are donated from the other
subunit, providing the structural basis for TS being an obligate dimer
(10). In addition, structures of binary (e.g. TS-dUMP,
TS-CH2H4-folate, or TS
bound to novel inhibitors) and ternary complexes (e.g.
TS-dUMP-folate analog, TS-dUMP
analog-CH2H4-folate, or
TS complexed with two analog inhibitors) have provided important information on key domains, chemical reactions, and conformational changes that occur during catalysis (10-14).
The active site of all known TS enzymes, with one exception, contains
the amino acid sequence PCH. After formation of the reversible ternary
complex with dUMP and CH2H4-folate, the
reactive thiol of the cysteine (Cys-195) within this motif initiates
the enzymatic reaction via nucleophilic attack at C-6 of dUMP. However, site-directed mutagenesis of these three residues has demonstrated that
both Pro-194 and His-196 can tolerate specific substitutions in
L. casei and E. coli without significant loss of
catalytic activity (15, 16). The catalytic cysteine (Cys-195) was found to be immutable when tested by complementation in L. casei
(17), but the constructed mutant C195S retains activity in E. coli. (7). Nucleotide sequence alignments indicate that TS is
phylogenetically one of the most highly conserved enzymes known (18).
However, it has become increasingly apparent that many amino acid
residues that are conserved in nature are tolerant to a variety of
substitutions in vitro (19).
In cells, 5-FU is metabolized to 5-FdUMP, which forms a stable
inhibitory complex with thymidylate synthase and the cosubstrate CH2H4-folate (19-21). In the ternary complex,
one covalent bond links the thiol group of Cys-195 to the C-6 of dUMP,
and a second covalent bond links the C-5 of the pyrimidine ring to the
one carbon unit (C11) of CH2H4-folate (19). Due
largely to its effective inactivation of TS, 5-FU is widely used in the
treatment of many common carcinomas including colon, breast, and
ovarian cancers. Although 5-FU is a potent anti-tumor
compound, its toxicity toward normal bone marrow and
gastrointestinal tissues limits its use (22). Genetic transfer of a
mutant TS enzyme that is resistant to inactivation by 5-FdUMP could
protect these tissues from 5-FU toxicity. The basis for such a genetic
rescue has been established for other proteins. For example, transfer
of a mutant dihydrofolate reductase cDNA into mouse bone marrow
stem cells has been shown to improve the survival of mice treated
subsequently with methotrexate (23, 24). Recently, retroviral-mediated
transfer of the gene encoding the human MGMT DNA repair protein has
been shown to confer protection of hematopoetic cells against
alkylating agents in vivo and in vitro (25,
26).
In the present work, we illustrate a unique approach for obtaining
mutants of TS that are catalytically active and are resistant to
inhibition by 5-FdUMP. Since 5-FdUMP is structurally similar to the
natural substrate dUMP, we lack adequate knowledge to design such
mutants by site-directed mutagenesis; it is difficult to predict how
single amino acid substitutions or multiple substitutions could
restrict the binding of 5-FdUMP without affecting binding of dUMP.
Random mutagenesis provides a combinatorial method to create altered
enzymes without requiring detailed knowledge about amino acid
interactions or effects of specific alterations. Based on sequence
homology alignment and crystallographic information, we targeted a
region for mutagenesis near the catalytic Cys-195 that assists in
formation of the dUMP binding site. We used genetic complementation to
obtain a collection of catalytically active mutants with amino acid
replacements in the active site of TS. These active mutants were
subsequently selected for their ability to confer growth of E. coli in the presence of 5-FdUR.
 |
EXPERIMENTAL PROCEDURES |
Cell Lines and
Materials--
CH2H4-folate was from Schircks
Labs (Jona, Switzerland). 5-[6-3H]FdUMP was supplied by
Moravek Biochemicals (Brea, CA). [ -32P]ATP and Thermo
Sequenase kits for DNA were obtained from Amersham Pharmacia Biotech.
ABI Prism Dye Terminator Cycle Sequencing kits for fluorescent
sequencing were the products of Perkin Elmer. E. coli DNA
Pol I was from New England Biolabs. Plasmid DNA was isolated using the
Maxiprep and Miniprep kits from Qiagen (Chatsworth, CA). 5-FdUR,
5-FdUMP, dUMP, TES, and all other reagents were from Sigma. E. coli NM522 (Stratagene) was used for cloning and library construction. E. coli 2913recA ( thyA572,
recA56), kindly provided by Dr. Daniel Santi (University of
California, San Francisco), is tetracycline resistant and was used in
all complementation studies and in the purification of plasmid-encoded
TS. Unless otherwise stated, all DNA oligomers were from Operon
Technologies (Alameda, CA).
Plasmids--
Plasmid pGCHTS-TAA, from D. Santi, contains the
wild-type human thymidylate synthase cDNA modified by the addition
of a 115-base pair 5'-untranslated region from the L. casei
TS in a high copy number modified pUC vector background (8, 27). A
unique translationally silent MroI site was added at coding
nucleotide 648 of the human TS vector pGCHTS by using the mega-primer
method of oligo-directed mutagenesis (28-30). Briefly, a 113-bp PCR
product was created by amplification with the primer DLTS2F with the
29-mer mutagenic primer BSPE1DL. DLTS2F is an 18-mer, which corresponds
to nucleotides 529-546 of the sense strand, and BSPE1DL corresponds to
the antisense nucleotides 644-661 with a G to A substitution at
nucleotide 648. The 133-bp PCR product was purified and used as a
mega-primer in a PCR reaction in conjunction with the primer 3'-HSG, a
20-mer corresponding to the antisense sequence of pGCHTS approximately 33 bp downstream of the SacI site used to clone the human
TS. The resulting 479-bp DNA fragment was subsequently digested with BglII and SacI and ligated into the corresponding
portion of the TS vector. A TS stuffer vector was created by replacing
the TS open reading frame between coding nucleotides 555 (BglII site) and 646 (MroI site) with a
1.3-kilobase DNA fragment derived from a modified pET3a vector
(Novagen, Madison, WI). The DNA insert was prepared by digestion of
pET3a with MroI and BglII agarose gel
purification of the appropriate fragment and ligation into the
MroI-BglII digested TS vector.
Construction of the TS Random Library--
The TS random library
was constructed by annealing two single-stranded DNA oligomers
(step 1, Fig. 1). Oligomer 1 is a 57-mer that corresponds to
the sense nucleotides 529-585 and contains a BglII site
(nucleotide 555) for cloning. Oligomer 2 is the 94-mer that contains a
mutated sequence corresponding to amino acids 197-200 and 205-213,
with 14% random nucleotides and 86% wild-type nucleotides at each of
the 39 randomized positions and an MroI site for cloning
(Table I). It was synthesized by
Integrated DNA Technologies (Coralville, IA). The random oligomer
contained on average 5.5 nucleotide changes, and thus we calculated
that 0.3% of the oligomer population was wild type at the nucleotide level (0.8639 = 0.0027). Two silent mutations were
introduced in the non-random region to create a unique SnaB1
site for subsequent identification based on digestion with the
restriction enzyme. Oligomers 1 and 2 were annealed in 50 µl of 200 mM Tris-HCl, pH 7.5, 100 mM MgCl2, 250 mM NaCl by incubation at 80 °C for 5 min, followed
by 55 °C for 15 min, at 37 °C for 15 min, and at room temperature
for 15 min (step 1, Fig. 1). The partial oligonucleotide
duplex was extended in a 40-µl reaction mixture containing 10 mM Tris-HCl (pH 7.5), 5 mM MgCl2,
7.5 mM dithiothreitol, 250 µM dNTPs, and 5 units of Klenow fragment of E. coli DNA Pol I for 2 h
at 37 °C (step 2, Fig. 1). The double-stranded
oligonucleotides were then amplified in a 100-µl polymerase chain
reaction containing 20 mM Tris-HCl, pH 8.75, 10 mM KCl, 10 mM
(NH4)2SO4, 2 mM
MgSO4, 0.1% Triton X-100, 100 µg/ml bovine serum
albumin, 1 µM primers DLTS2F and DLTS3R, and 2.5 units of
Pfu DNA polymerase (Stratagene). The reaction mixture was
heated for 30 cycles in a programmable thermal controller (MJ Research,
Watertown, MA) at 95 °C for 1 min, 50 °C for 1 min, and 72 °C
for 1 min (step 3, Fig. 1). DLTS2F, described above, corresponds identically to the 5'-end of oligomer 1. DLTS3R is a 32-mer
corresponding to antisense nucleotides 636-658 and is identical to the
3'-end of oligomer 2 with the addition of a 5'-9-bp oligo-A overhang to
facilitate subsequent restriction digestion. The amplified DNA was
digested with BglII (New England Biolabs) and
MroI (an isoschizomer of BspE1; Boehringer
Mannheim) (step 4, Fig. 1), separated via centrifugation
through a Microcon-30 filter (Amicon) and extracted with phenol.
Replacement of Wild-type TS Sequence with the Random
Library--
The purified partially random oligonucleotides were used
as inserts for construction of the human TS plasmid library. The stuffer vector was removed by digestion with BglII and
MroI, and the resulting 3.6-kilobase fragment was isolated
from a 0.8% agarose gel and was ligated to the 95-bp restricted random
insert using T4 DNA ligase (Life Technologies, Inc.) (step
5, Fig. 1). The ligation mixture was directly transformed (Bio-Rad
Genepulser, 2 kV, 25 µFD, 400 Ohm) into electrocompetent NM522 cells
(Stratagene) (step 6, Fig. 1) using 2 µl of the ligation
mixture (containing 100 ng of backbone and a 5:1 molar ratio of random
insert to cut plasmid DNA), and 100 µl of E. coli yielded
on average 2-6 × 104 transformants. Thirty
transformations were pooled to obtain a library size of 2 × 106 clones. The size of the library containing the TS
plasmid was determined by plating an aliquot of the transformation
mixture on media containing carbenicillin (50 µg/ml; Island
Scientific, Bainbridge Island, WA). The remainder of the library was
amplified by growing the transformed NM522 cells overnight in 1 × YT media in the presence of carbenicillin and recovering the plasmid
(step 7, Fig. 1). Transformation into 2913
(TS ) E. coli was conducted using 500 ng of the
purified plasmid DNA library and 100 µl of electrocompetent cells.
(Bio-Rad Genepulser, 1.8 kV, 25 µFD, 400 Ohm). Five separate
transformations were pooled, and cells were grown overnight in
nonselective medium containing 50 µg/ml carbenicillin, 10 µg/ml
tetracycline, and 50 µg/ml thymidine and stored in aliquots at
80 °C in 10% glycerol (step 8, Fig. 1). The extent of
randomization was verified by sequencing plasmid DNA from 35 clones
grown on nonselective 2 × YT medium as described above.
Genetic Selection in E. coli--
Mutants encoding active TS
were selected by the method of Belfort and Pedersen-Lane (31). Only
2913 E. coli cells that produce functional TS are capable
of colony formation on media lacking thymidine. 2913 cells
containing the random library were grown overnight at 37 °C in
1 × YT medium containing the appropriate antibiotics. The culture
was diluted 1:100 with the same medium and grown at 37 °C until the
absorbance at 600 nm attained a value of 0.8 to 1.0. Aliquots of 1 ml
of the exponentially growing cells were pelleted and resuspended in M9
salts, plated on minimal medium containing carbenicillin and
tetracycline, and incubated at 37 °C for 36 h. Plasmids were
isolated from 39 surviving colonies, and the inserted sequences
containing the random region were sequenced to determine amino acid
changes tolerable in maintaining catalytic activity of TS.
To select for library members that are resistant to killing with
5-FdUR, transformants were placed on minimal medium in plates with
increasing amounts of 5-FdUR (0-150 nM 5-FdUR) and
incubated at 37 °C for 36 h. Colonies that grew in 5-FdUR were
isolated, and the plasmid was retransformed into fresh 2913 E. coli to confirm the drug-resistant phenotype and eliminate false
positives. Each retransformed mutant was then subjected to the same
selection procedure. Appropriate dilutions were conducted ranging from
10 2 to 10 6 such that plates contained
approximately 1000 colonies. DNA from those mutants that survived 125 or 150 nM FdUR (n = 53), which was lethal
to E. coli harboring the wild-type TS, was sequenced.
Purification of Wild-type and Mutant TS--
To construct a
plasmid expressing the wild-type or a mutant TS enzyme (Mut 64) linked
to a 6×-His polypeptide, the 981-bp TS-containing DNA fragment of
pGCHTS-TAA and Mut 64 were PCR amplified by using the 5' primer TS-NDE1
and the 3' primer TS-SALI. TS-NDEI hybridizes to the N-terminal
sequence of TS, which naturally contains an NdeI restriction
site; primer TS-SALI contains a SalI restriction site and a
5'-oligo-A tail and hybridizes to the sequence encoding the terminal 16 nucleotides of TS. The amplified DNA was cloned into pHis (a modified
pUC12 vector provided by A. Hizi) and similarly digested with
NdeI and SalI. Cloning procedures were confirmed by both restriction analysis and DNA sequencing. The TS-6×-His fusion
proteins were purified by a one-step metal chelation chromatographic procedure, using Ni2+ affinity resin and buffers (His-Bind
resin and buffer kit, Novagen) according to a protocol modified from
the supplier. TS containing 2913 E. coli cells (250 ml),
derived from overnight incubation of a single colony, was diluted 1:100
in fresh 2 × YT medium containing carbenicillin. After attaining
an absorbance at 600 nm of 1.0, the bacteria were harvested by
centrifugation, resuspended, and frozen at 80 °C in 30 ml of
1 × binding buffer (5 mM imidazole, 500 µM NaCl, 20 mM Tris-HCl, pH 7.9) and lysozyme
(200 µg/ml, Sigma). Frozen cells were thawed and lysed on ice for
approximately 3 h. The lysed cells were centrifuged (27,000 × g), and the supernatant was applied to a charged 2.5-ml
His-Bind column (1 × 2.5 cm). The resin was prepared by
successive washes with 30 ml of deionized water, 30 ml of 1 × charge buffer (50 mM NiSO4), and 30 ml of 1 × binding buffer. All chromatographic steps were carried out at
4 °C at a maximal flow rate of 20 ml/h. Following application of the
crude supernatant, the column was washed successively with 40 ml of
1 × binding buffer, 25 ml of a mixture containing 60% binding
buffer and 40% wash buffer (60 mM imidazole, 500 µM NaCl, 20 mM Tris-HCl, pH 7.9), and 10 ml
of 1 × wash buffer. TS was eluted with 30 ml of 1 × elution
buffer (1 M imidazole, 500 µM NaCl, 20 mM Tris-HCl, pH 7.9), and about 90% of the recovered TS
was released from the resin in the first 8 ml. Fractions (1.5 ml)
containing purified human TS were analyzed by SDS-PAGE. Fractions containing TS were combined (3 ml) and dialyzed against 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 200 mM NaCl, and 10% glycerol for 16 h and then against
the same buffer containing 1 mM dithiothreitol for an
additional 16 h. The concentration of purified TS was determined by FdUMP binding according to the methods of Moran et al.
(32).
TS Enzyme Assays--
TS activity was monitored
spectrophotometrically by the increase in absorbance at 340 nm that
occurs concomitant with the production of H2-folate ( = 6400 M 1 cm 1) (33, 34). The
standard reaction buffer contained 50 nM TES, pH 7.4, 25 mM MgCl2, 6.5 mM formaldehyde, 1 mM EDTA, and 150 µM 2-mercaptoethanol. When
the concentration of dUMP was varied, (6R)-CH2H4-folate was added at 150 µM; when CH2H4-folate was varied, the concentration of dUMP was 100 µM (>20
Km). Wild-type (10 nM) or Mut 64 (2.25 nM) TS was added to initiate the reaction. Steady-state
kinetic parameters were obtained by a nonlinear least squares fit of
the data to the Michaelis-Menten equation using Kalidegraph 3.0 software (Abelbeck Software, Reading PA).
Kinetic Analysis of FdUMP Binding--
Equilibrium studies of
FdUMP binding by wild-type TS were carried out in reaction mixtures
that contained 3.5 nM enzyme, 0.3-10.8 nM
[6-3H]FdUMP, and 150 µM
CH2H4-folate in TES buffer, pH 7.4. Equilibrium analysis of Mut 64 TS was conducted with 10 nM enzyme and
0.3-14 nM [3H]FdUMP. Equilibrium binding
mixtures were incubated for 6 h at 24 °C, and protein-bound
[3H]FdUMP was separated from free [3H]FdUMP
by centrifugation at 12,000 × g through a Microcon-10 filter (Amicon) and washed three times with TES buffer. The
flow-through (500 µl) containing free [3H]FdUMP was
added to 5 ml of Scinti-Verse scintillation fluid (Fischer), and the
radioactivity was quantitated. All data points were conducted in
duplicate. Values of apparent dissociation constants (Kd) were determined by computer-assisted linear
regression analysis of data graphed according to the Scatchard equation
(35) and were the average of three separate determinations.
 |
RESULTS |
Construction of the Random Sequence Library--
A library of
2 × 106 human (TS) mutants was created by random
sequence mutagenesis. The human TS gene expressed in the
plasmid, pGCHTS-TAA, was modified to include an MroI
restriction site at nucleotide 648. As illustrated in Fig.
1, a stuffer fragment was first inserted
and was subsequently replaced by an insert containing random
nucleotides. This allowed replacement of the targeted segment with a
large nonfunctional stuffer fragment. The insert was constructed by
elongating a partially double-stranded oligonucleotide containing 39 random nucleotides using DNA polymerase. It was digested with restriction enzymes to produce staggered ends and ligated into the
modified human TS plasmid to replace the stuffer fragment. The 39-base
pair randomized region encoding for TS residues 196-199 and 204-212
was located on the C-terminal side of the catalytically active cysteine
(Cys-195). Unlike the wild-type TS construct, the recombinant plasmid
contains a silent SnaBI site that was used to confirm that
any active clones with a wild-type DNA sequence are the result of
selection from the library and not contamination.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Scheme for random sequence mutagenesis of
human TS. Construction of a plasmid-borne library of TS variants
containing random nucleotide substitutions is shown corresponding to
residues 196-199 and 204-212. Synthesis of the random
nucleotide-containing oligonucleotides (inserts) is illustrated in
steps 1-4; (X)39 in oligomer 2 denotes 39 non-contiguous residues containing 14% random nucleotides at each
residue. Ligation of the inserts into the dummy vector, to replace the
wild-type TS sequence at residues 196-199 and 204-212, is shown in
step 5. Preparation of the plasmid library in
TS E. coli is outlined in steps
6-8.
|
|
Sequencing of Nonselected Clones to Determine Diversity of
Library--
Prior to selection, plasmid DNA was isolated from 35 transformed clones and sequenced. The number of substitutions per clone is presented in Fig. 2, and the types of
substitutions are tabulated in Fig. 3. As
seen in Fig. 2A, an average of 5.7 nucleotide changes and
4.3 amino acid changes per clone was detected. Amino acid substitutions
in the nonselected clones were evenly distributed among the 13 residues
encoded by the randomized nucleotides (Fig. 3A). 9 of the 35 nonselected clones analyzed (26%) contained at least one frameshift
mutation, and 5 contained termination codons. The substitutions
observed were in accord with the expected distribution in the plasmid
population (36). Based on the number and frequency of random
substitution, we calculated that the nonselected library should contain
approximately 0.27% wild-type nucleotide sequences corresponding to
1% wild-type protein sequence (see "Discussion" for calculation).
Therefore, it is not surprising that one wild-type molecule was
detected among the 35 nonselected clones sequenced.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 2.
Number of amino acid substitutions.
A, nonselected mutants; B, active mutant library;
C, 5-FdUR-selected mutant library. 35 clones were sequenced
from the nonselected library, and it was determined, on average, that
there were 5.7 nucleotide changes and 4.2 mutations per clone,
including frameshift and nonsense mutations. 39 clones were sequenced
from the pool of mutants that demonstrated the ability to complement
the TS phenotype of 2913 E. coli
(comprising the active mutant library), and it was found that, on
average, there were 3.0 nucleotide changes and 1.4 amino acid
substitutions per mutant. 52 clones were sequenced from the
5-FdUR-selected library, demonstrating an average of 4.7 nucleotide and
2.2 amino acid substitutions per mutant.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Amino acid substitutions. A,
nonselected; B, active mutant library; C,
5-FdUR-selected library. The wild-type TS sequence is shown
below the solid line, and the substitutions
observed at each position are indicated above each site.
Boxed residues are those subjected to mutagenesis. The
catalytic cysteine, Cys-195, is absolutely conserved
(underlined). A number following a substitution
indicates the number of nucleotides observed to be mutated in the
corresponding codon; no number is shown if only one
nucleotide was altered. B, active clones consisting of 2 amino acid substitutions include V204G/C199I, V204F/S206R, E207R/Q211H,
A197T/L208V, and C199S/V204M. Active clones harboring triple substitutions include
V204G/N205D/L212M, A197S/C199F/N205K, V204L/N205H/Q211H,
V204L/N205K/S206K, and V204D/N205H/E207G. No active clones contained
more than three amino acid alterations. C, in addition to
the mutations shown, one of the variants encoded a mutation in the
nonrandomized sequence P193S. The sequences of the individual
5-FU-resistant clones are depicted in Table III.
|
|
Selection and Sequencing of E. coli Expressing Active Thymidylate
Synthase--
The isolation of active enzymes from large plasmid
libraries containing random sequences is facilitated by stringent
positive genetic complementation. We first defined conditions under
which there is a substantial difference in survival between bacteria expressing and not expressing active human thymidylate synthase. Whereas the wild-type TS construct was able to rescue the
TS E. coli phenotype and formed colonies on
minimal medium, E. coli harboring the stuffer vector that
inactivates TS did not. Approximately 10% of the nonselected random
library encoded functional enzymes (105 mutants). DNA from
39 mutants was sequenced without detecting any nucleotide substitutions
or frameshift mutations. The corresponding amino acid substitutions are
depicted in Fig. 3B. Wild-type protein sequence was observed
in 11 clones (28%), and each contained the two silent mutations,
indicating they did not result from contamination with wild-type
plasmids.
Selection and Sequencing of E. coli Expressing Active TS Resistant
to 5-Fluorodeoxyuridine--
To isolate members of the random enzyme
library demonstrating selective resistance to 5-FdUMP, an additional
positive genetic selection was employed by supplementation of the
minimal medium with a gradient of 5-FdUR concentrations. In preliminary
experiments, we established that survival of the E. coli
harboring wild-type TS was only modestly reduced to 90% at 75 nM 5-FdUR compared with controls in the absence of 5-FdUR.
However, survival precipitously declined to 0.1% at 100 nM
of the analog. No surviving wild-type clones were detected at dosages
above 100 nM (Fig. 4). In
contrast, approximately 0.1% of the E. coli harboring the
random library formed colonies at 5-FdUR concentrations as high as 150 nM. In a typical experiment, colony formation by E. coli harboring plasmids with random inserts at 150 nM
5-FdUR was approximately 10 3 that of untreated E. coli (Table II). Individual colonies
were isolated from plates containing 150 nM 5-FdUR
(n = 79), and plasmid DNA was retransformed into fresh
2913 to confirm the drug-resistant phenotype. DNA from those mutants
that formed colonies upon a second exposure to 5-FdUR at a dose that
was clearly lethal to the wild-type enzyme (125 or 150 nM,
n = 52) was sequenced in the random region, and the
corresponding amino acid changes were deduced (Fig. 3C).
Although the wild-type enzyme was present in 28% of the active TS
mutant library, no wild-type sequences were detected among the
5-FdUR-treated survivors. This suggests that we have indeed selected
mutants that are more resistant to 5-FdUR than those encoded by the
wild-type sequence.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Survival of TS mutants incubated with
5-FdUR. 2913 cells expressing wild-type and TS mutants were
grown on minimal media containing 5-FdUR for 36 h. Survival was
determined by counting colonies at each dose of 5-FdUR and is expressed
as a fraction of the survival of untreated cells. The triple mutant
A197V/L198I/C199F is Mut 64.
|
|
Of the 52 mutants sequenced, no two mutants were identical at the
nucleotide level. However, clones containing only the single mutation
C199L or A197F were detected in multiple occurrences (6 and 2, respectively, Table III). All clones with
multiple mutations at the amino acid level were unique. One mutant, Mut
64, demonstrated the highest survival at both 125 and 150 nM (Fig. 4) and was found to include three adjacent
mutations: A197V, L198I, and C199F.
View this table:
[in this window]
[in a new window]
|
Table III
Human thymidylate synthase clones surviving 5-FdUR selection
The deduced amino acid changes in mutants resistant to 5-FdUR and the
number of amino acid (AA) and nucleotide (nt) changes in each mutant
are indicated. The wild-type sequence is indicated above the line, with
the 13 randomized positions in underlined italics. In addition to the
clones shown, one clone contained a mutation in the non-random sequence
(Mut 18: P193S), yielding a total of 52 clones sequenced.
|
|
The spectrum of mutations observed in the 5-FdUR-selected library
differed from the spectrum of active mutants at multiple key amino acid
residues, most notably Ala-197 and Cys-199. Among the active TS
library, Ala-197 was found to be mutable to Thr, Val, and Ser. Notably,
A197F was not detected, indicating that it was not selected solely on
the basis of activity. By contrast, A197F was found in 5 of 11 (45%)
mutants in the 5-FdUR-selected library. Similarly, Cys-199 was altered
to Tyr, Ser, Ile, or Phe in the active mutant library, whereas in the
drug-resistant library, the mutation C199L was detected in 24 of the 52 (46%) 5-FdUR-resistant clones. The nucleotide substitutions observed
generating the C199L mutations were predominantly double (and one
triple) nucleotide changes. Three clones contained only the single
mutation C199L, yet each of the three differed by the presence of
silent nucleotide changes.
Purification and Kinetic Analysis of Wild-type and Mut 64 Thymidylate Synthase--
To study the mechanism of FdUR resistance,
we purified wild-type and Mut 64 enzymes and conducted kinetic
analysis. Both were subcloned, resequenced, and expressed in E. coli as N-terminal fusions with a histidine tag. This allowed a
one-step purification using nickel chelation chromatography. SDS-PAGE
analysis demonstrated a single predominant TS band at 36 kDa with an
estimated purity of the wild-type enzyme of >95% and Mut 64 TS >85%
(Fig. 5). The mutant enzyme preparation
contained two minor protein bands of approximately 29 and 9 kDa. The
sum value of their molecular mass (~38 kDa) as well as their
equimolar ratio indicate they may represent TS degradation
products.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of purified TS by 12%
SDS-PAGE. Preparations of the wild-type (WT) and the triple
mutant, Mut 64, were purified by Ni2+ chelation
chromatography. Either 2 or 6 µg of each purified protein was
subjected to SDS-PAGE and detected by Coomassie Blue staining.
|
|
As seen in Table IV, although kinetic
parameters of Mut 64 for the normal substrates were nearly identical to
that of the wild-type enzyme, the dissociation constant for 5-FdUMP was
nearly 20 times greater. The Km value for dUMP for
Mut 64 (2.5 ± 0.4 µM) was not significantly
different than that of the wild-type enzyme (1.8 ± 0.7 µM); the Km for
CH2H4-folate (28 ± 9 µM)
was at most marginally increased in the mutant enzyme relative to
wild-type TS (14 ± 5 µM). The steady-state rate of
the reaction, kcat, was found to be essentially
unchanged in the FdUR-resistant mutant relative to the wild-type
protein (Table IV). kcat/Km ratios of both dUMP and CH2H4-folate
demonstrate that the triple mutant is an equally efficient enzyme
compared with the wild type. To determine the relative binding of the
covalent inhibitor 5-FdUMP into TS, equilibrium binding studies
measuring the formation of the ternary complex were conducted. A
Scatchard plot of the binding data (Fig.
6) demonstrated that both TS forms
contain a single class of FdUMP binding sites. The
Kd values were determined by averaging three
different experiments, and the mutant form was found to have a
Kd for FdUMP of 2.3 ± 0.9 × 10 9 M, whereas the wild-type
Kd was determined to be 1.1 ± 0.4 × 10 10 M (Table IV). The 20-fold increase in
Kd of Mut 64 is likely representative of the
increased discrimination of the mutant between uridylate and its
fluorinated counterpart. These kinetic data indicate that Mut 64 is
functionally a quite similar enzyme to the wild type, differing
primarily in its behavior toward 5-FdUMP.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Determination of the dissociation constant
for FdUMP binding to wild-type and Mut 64 TS. Purified wild-type
TS (3.5 nM) or Mut 64 (10 nM) was incubated for
6 h at 24 °C with 150 µM
CH2H4-folate and increasing amounts (0.3-14.4
nM) of [6-3H]FdUMP. The
TS-CH2H4-folate-[6-3H]FdUMP
complex was resolved as described under "Experimental Procedures."
Values of dissociation constant, Kd, were inferred
from the negative reciprocal of slopes of data plotted according to the
Scatchard equation (35). Shown are typical plots obtained with
wild-type TS (A) and Mut 64 (B).
|
|
 |
DISCUSSION |
As a first step toward creating novel TS variants, we used random
sequence mutagenesis to alter the active site of the human TS. We
generated a large library of TS substitutions spanning residues
196-199 and 204-212. Based on the crystal structure of the E. coli and human TS, many of these residues are likely to form the
wall of the active site cavity, and, therefore, amino acid
substitutions are likely to cause subtle changes in binding pyrimidine-based analogs. Absolutely conserved residues, such as
Pro-194 and Cys-195, were left unaltered. Although completely conserved
in nature, His-196 has been mutated in both E. coli (His-147) and L. casei (His-199) to non-bulky residues,
resulting in active enzymes that function in a genetic complementation
assay (15, 16). Hence, His-196 was included in the randomized region. To emphasize the most critical residues, the number of random substitutions should be minimized. Residues 200-203 were left unrandomized because they are either absolutely (Gln-200 and Val-203) or highly (Phe-201 and Tyr-202) conserved, allowing for a contiguous stretch of four residues to remain unaltered. To our knowledge, among
residues in our random region, only His-196 has been subjected to
mutagenesis by other groups (15, 16). No alterations in this residue
have been screened for 5-FdUR resistance.
Thymidylate synthase has been subjected to extensive mutagenesis by
many laboratories. A thorough review of these active mutants has been
conducted by Carreras and Santi (19). However, less is known about
alterations that can confer selective resistance to 5-FdUR. Zhang
et al. (37) have created a mutation in a conserved loop
guarding the active site of the mouse TS (R44V), which demonstrates a
large reduction in the binding of both dUMP and FdUMP, and a 100-fold
reduction in the catalytic activity (37). Although several authors have
reported the discovery of altered TS molecules that demonstrate 5-FdUR
resistance (38-43), in only one such mutant has the substituted amino
acid been identified. A 5-FU-resistant HCT116 colonic tumor cell line
was found to encode for the single mutant Y33H. This mutant has a
Kd value approximately 3-4-fold higher than the
wild-type enzyme in the absence of any large alterations in catalytic
efficiency or affinity for dUMP or CH2H4-folate
(44).
Substitutions That Retain Activity Differed in Many Respects
Compared with the Nonselected Random Library--
The members of the
random library that were selected by their ability to complement a
TS- E. coli contained on average far fewer amino
acid substitutions than the nonselected library (Fig. 2, A
and B). This is probably a reflection that a large number of
substitutions are intolerable in the active site of TS. All frameshift
and nonsense mutations were eliminated (Fig. 3, A and
B). Wild-type protein sequence was observed in 28% of the
clones, approximately 20 times that observed in the nonselected
library. In addition, differential survival of the library on medium
with and without thymidine demonstrated that approximately 90% of the
nonselected library is unable to complement the TS-
E. coli. Both pieces of data indicate the active mutant library contains approximately 105 unique clones. Compared with the
nonselected library, the substitutions catalogued in the selected
population were more conservative. However, all residues in the random
region, with the exception of His-196 and Cys-210, tolerated
substitutions, indicating the high degree of plasticity of the selected
region. Substitutions at His-196 may not have been detected in our
sequencing of 39 of approximately 105 TS variants, and two
substitutions observed in Cys-210 in the drug-selected library indicate
this residue is not immutable. By far, most of the amino acid
substitutions were the result of single nucleotide substitutions (44 of
53 substitutions), as expected by the greater probability of creating
one nucleotide change relative to two or more.
The 5-FdUR-selected Library Is Further Restricted--
In the
drug-treated library, the average number of amino acid substitutions is
greater than that in the active library (mean = 2.2 versus 1.4). Not only is the wild type eliminated, but there are a greater proportion of double mutants (Table III, Fig.
2C). The 5-FdUR-selected library essentially consists of
only a small subset of the active library mutant population; there was
approximately a 1000-fold killing observed between the non-drug-treated
active mutant library and the library exposed to 150 nM
5-FdUR. In addition, the spectrum of mutations differed. For example,
C199L was not detected in any of the 39 clones sequenced from the
active library, yet it was present in 46% of the 5-FdUR-selected
library (24 of 52 clones). The frequency of double and triple
nucleotide substitutions at residue Cys-199 demonstrates the stringency
of 5-FdUR selection. Any alteration in Cys-199 resulting in a leucine
(TGC to CTN, TTA, or TTG) requires at least two mutations. The number
of double nucleotide mutations that create a C199L alteration in a
library of 105 active clones can be calculated using the
equation PC L = PTGC CTN + PTGC TTA + PTGC TTG = (r/3)2(1) + (1 r)(r/3)2 + (1 r)(r/3)2 = 0.0060, where
PC L is the probability of residue 199 being altered to leucine, PTGC NNN is the
probability of a given double nucleotide alteration, and r
is the percent randomness, i.e. the probability that one
particular nucleotide is substituted for any of the three remaining
bases (14%). From a library of 105 active mutants, we
would expect only 600 clones to contain a C to L substitution (0.6%);
yet, we have detected 24 clones in the drug-resistant library after
sequencing just 52 survivors (46%). Even more striking is the number
of clones that contain only the single substitution alteration C199L.
Assuming that there are on average 3 codons per amino acid,
ax = 1 (1 r)2 (1 r/3) = 0.295, where
ax is the probability of substitution of an
amino acid at a given residue (36) and r is 14% as
described above. In the 13 randomized residues, a wild-type protein
will occur at a frequency of (1-0.295)13 = 1%. The
probability of obtaining a clone with only the mutation C199L would be
(1-0.295)12 (0.0060) = 9 × 10 5. In a
library of 105 mutants, we expect only 9 clones to contain
only the C200L mutation in the absence of selection (0.0006%).
Remarkably, we have detected six unique C200L mutants in our sequencing
of just 52 drug-resistant mutants (12%). Parallel arguments can be
made for substitutions for other residues, indicating that
over-representation of certain amino acid substitutions in the
drug-selected library is associated with increased ability to survive
5-FdUR treatment in E. coli .
Kinetic Analysis of Mut 64 Reveals Decreased Binding of FdUMP
Relative to the Wild Type--
Of the TS variants surveyed, the triple
mutant Mut 64 was the most resistant to 5-FdUR. Not only was its
survival rate consistently higher at each drug dose, the colony size of
E. coli harboring Mut 64 was on average larger and less
heterogeneous than that formed by E. coli expressing the
other mutants. This mutant carried alterations in three adjacent
residues next to the active site conserved PCH sequence. The
substitutions, A197V/L198I/C199F, were conservative relative to
hydrophobicity. Valine occurs naturally in position 197 in Saimirine
herpesvirus I, Ateline herpesvirus 2, and Candida albicans
TS enzymes (19). Although Ile-198 has not been reported in nature, it
is a conservative change. Phenylalanine at position 199 is found in
both E. coli and Bacillus subtilis TS.
The similarity in Km values for both dUMP and the
cosubstrate CH2H4-folate between Mut 64 and the
wild type indicate that the triple alterations in Mut 64 do not
significantly affect interactions with either substrate. In addition,
the kcat of Mut 64 is only slightly decreased
compared with the wild type. In fact, the overall efficiency of the
mutant enzyme, as measured by the
kcat/Km ratio, indicates that
Mut 64 is very similar to that of the wild-type enzyme (Table IV). Yet,
equilibrium binding studies have determined that Mut 64 displays a
marked decrease in the dissociation constant compared with wild type.
The Kd obtained for the wild-type TS (1.1 ± 0.4 × 10 10 M) is in agreement with the
published value (38). The Kd for Mut 64 (2.3 ± 0.9 × 10 9 M) is 20 times that of the
wild-type enzyme, indicating that alteration of the three adjacent
residues may alter the structure of TS in subtle ways such that the
enzyme can discriminate between the fluorinated and non-fluorinated
pyrimidine ring.
Potential Applications--
Random sequence mutagenesis coupled to
a positive genetic selection provides a novel approach to creating
altered TS molecules with desired properties; here we have presented
the engineering and identification of mutants of TS that demonstrated
resistance to 5-FdUR. An analogous approach using random mutagenesis
and genetic complementation in E. coli can be developed for
other clinically relevant TS inhibitors as they are developed. Although site-directed mutagenesis of TS has been used to identify residues required for catalytic activity, this approach is limited because residues are ultimately tested one at a time, and we lack rules to
predict the effects of multiple substitutions. Effective site-directed mutagenesis requires detailed knowledge about amino acid interactions and predictions regarding the effects of specific alterations. Random
mutagenesis provides a combinatorial alternative in which a detailed
understanding of the changes necessary to create variants is not
required.
Despite its efficacy in the treatment of many human malignancies, the
use of 5-FU has been limited by toxicity to bone marrow, gastrointestinal, and other tissues (22). The introduction and expression of variants of TS that function in the presence of systemic
5-FU treatment could protect normal cells from the cytotoxic side
effects of this drug or conversely allow the use of increased amounts
of 5-FU to be safely administered. In addition, understanding the
mechanisms by which TS can become 5-FU resistant is of importance not
only for potential uses in gene therapy; tumors have been identified
that are refractory to treatment with 5-FU due to mutations (39-43)
and overexpression of TS (45-47). A better understanding of the
structural basis of drug resistance could perhaps lead to the design of
more clinically effective pyrimidine or anti-folate inhibitors of
TS.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Dan Santi and Pat Greene for
the generous gift of bacterial strains, the human TS plasmid, technical
assistance, and frequent discussions, Dr. Ellie Adman for molecular
modeling and crystallographic interpretation, Dr. Albert Mildvan for
critical comments, and Dr. Mickey Fry for critical reading of this
manuscript.
 |
FOOTNOTES |
*
This work was supported by the Outstanding Investigator
Grant R35-CA-39909, National Institutes of Health (to L. A. L.),
Medical Scientist Training Program Grant NIH NIGMS 5 T32 07266 (to
D. M. L.), and the Cora May Poncin Scholarship Fund (to D. M. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pathology,
The Joseph Gottstein Memorial Cancer Research Laboratory, University of
Washington School of Medicine, Box 357705, Seattle, WA 98195-7705. Tel.: 206-543-6015; Fax: 206-543-3967; E-mail: laloeb{at}u.washington.edu.
The abbreviations used are:
TS, thymidylate
synthase; 5-FdUR, 5-fluoro-2'-deoxyuridine; 5-FU, 5-fluorouracil; FdUMP, 5-fluoro-2'-deoxyuridine 5'-monophosphate; CH2H4-folate, (6R,S)-N5,N10-methylene-5,6,7,8-tetrahydrofolateTES, N-tris[hydroxymethyl]methyl-2-aminoethane-sulfonic
acidbp, base pair(s)PCR, polymerase chain reactionPAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
-
Cohen, S. S.,
and Barner, H. D.
(1954)
Proc. Natl. Acad. Sci., U. S. A.
40,
885-893[Free Full Text]
-
Seno, T.,
Ayusawa, D.,
Shimizu, K.,
Koyama, H.,
and Takeishi, K.
(1985)
Basic Life Sci.
31,
241-263[Medline]
[Order article via Infotrieve]
-
Goulian, M.,
Bleibe, B.,
and Tseng, B. Y.
(1980)
Proc. Natl. Acad. Sci., U. S. A.
77,
1956-1960[Abstract/Free Full Text]
-
Rode, W.,
Scanlon, K. J.,
Moroson, B. A.,
and Bertino, J. R.
(1980)
J. Biol. Chem.
255,
1305-1311[Abstract/Free Full Text]
-
Santi, D. V.,
and Danenberg, P. V.
(1984)
in
Folates in Pyrimidine Nucleotide Biosynthesis (Blakley, R. L., and Benkovic, S. J., eds), pp. 345-398, John Wiley & Sons, New York
-
Harrap, K. R.,
Jackman, A. L.,
Newell, D. R.,
Taylor, G. A.,
Hughes, L. A.,
and Calvert, A. H.
(1989)
Adv. Enzyme Regul.
29,
161-179[CrossRef][Medline]
[Order article via Infotrieve]
-
Hardy, L. W.,
Finer-Moore, J. S.,
Montfort, W. R.,
and Jones, M. O.
(1987)
Science
235,
448-455[Abstract/Free Full Text]
-
Schiffer, C. A.,
Clifton, I. J.,
Davisson, V. J.,
Santi, D. V.,
and Stroud, R. M.
(1995)
Biochemistry
34,
16279-16287[CrossRef][Medline]
[Order article via Infotrieve]
-
Matthews, D. A.,
Appelt, K.,
Oatley, S. J.,
and Xuong, N. H.
(1990)
J. Mol. Biol.
214,
923-936[CrossRef][Medline]
[Order article via Infotrieve]
-
Montfort, W. R.,
Perry, K. M.,
Fauman, E. B.,
Finer-Moore, J. S.,
Maley, G. F.,
Hardy, L.,
Maley, F.,
and Stroud, R. M.
(1990)
Biochemistry
29,
6964-6977[CrossRef][Medline]
[Order article via Infotrieve]
-
Webber, S. E.,
Bleckman, T. M.,
Attard, J.,
Deal, J. G.,
Kathardekar, V.,
Welsh, K. M.,
Weber, S.,
Janson, C. A.,
Matthews, D. A.,
Smith, W. W.,
Freer, S. T.,
Jordan, S. R.,
Bacquet, R. J.,
Howland, E. F.,
Booth, C. L. J.,
Ward, R. W.,
Hermann, S. M.,
White, J.,
Morse, C. A.,
Hilliard, J. A.,
and Bartlett, C. A.
(1993)
J. Med. Chem.
36,
733-746[CrossRef][Medline]
[Order article via Infotrieve]
-
Shoicheck, B. K.,
Stroud, R. M.,
Santi, D. V.,
Kuntz, I. D.,
and Perry, K. M.
(1993)
Science
259,
1445-1450[Abstract/Free Full Text]
-
Eckstein, J. W.,
Foster, P. G.,
Finer-Moore, J.,
Wataya, Y.,
and Santi, D. V.
(1994)
Biochemistry
33,
15086-15094[CrossRef][Medline]
[Order article via Infotrieve]
-
Perry, K. M.,
Carreras, C. W.,
Chang, L. C.,
Santi, D. V.,
and Stroud, R. M.
(1993)
Biochemistry
32,
7116-7125[CrossRef][Medline]
[Order article via Infotrieve]
-
Michaels, M. L.,
Kim, C. W.,
Matthews, D. A.,
and Miller, J. H.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
3957-3961[Abstract/Free Full Text]
-
Dev, I. K.,
Yates, B. B.,
Atashi, J.,
and Dallas, W. S.
(1989)
J. Biol. Chem.
264,
19132-19137[Abstract/Free Full Text]
-
Climie, S.,
Ruiz-Perez, L.,
Gonzalez-Pacanowska, D.,
Prapunwattana, P.,
Cho, S. W.,
Stroud, R.,
and Santi, D. V.
(1990)
J. Biol. Chem.
265,
18776-18779[Abstract/Free Full Text]
-
Perry, K. M.,
Fauman, E. B.,
Finer-Moore, J. S.,
Montfort, W. R.,
Maley, G. F.,
Maley, F.,
and Stroud, R. M.
(1990)
Proteins
8,
315-333[CrossRef][Medline]
[Order article via Infotrieve]
-
Carreras, C. W.,
and Santi, D. V.
(1995)
Annu. Rev. Biochem.
64,
721-762[CrossRef][Medline]
[Order article via Infotrieve]
-
Santi, D. V.,
McHenry, C. S.,
Raines, R. T.,
and Ivanetich, K. M.
(1987)
Biochemistry
26,
8606-8613[CrossRef][Medline]
[Order article via Infotrieve]
-
Santi, D. V.,
McHenry, C. S.,
and Sommer, H.
(1974)
Biochemistry
13,
471-481[CrossRef][Medline]
[Order article via Infotrieve]
-
Grem, J. L.
(1990)
in
Cancer Chemotherapy: Principles and Practice (Chabner, B. A., and Collins, J. M., eds), pp. 180-224, J. B. Lippincott, Philadelphia
-
Williams, D. A.,
Hsich, K.,
DeSilva, A.,
and Mulligan, R. C.
(1987)
J. Exp. Med.
166,
210-216[Abstract/Free Full Text]
-
Carr, F.,
Medina, W. D.,
Dube, S.,
and Bertino, J. R.
(1983)
Blood
62,
180-185[Abstract/Free Full Text]
-
Moritz, T.,
Mackay, W.,
Glassner, B. J.,
Williams, D. A.,
and Samson, L.
(1995)
Cancer Res.
55,
2608-2614[Abstract/Free Full Text]
-
Marathi, U. K.,
Harris, L. C.,
Venable, C. C.,
and Brent, T. P.
(1997)
Clin. Can. Res.
3,
301-307[Abstract]
-
Davisson, V. J.,
Sirawaraporn, W.,
and Santi, D. V.
(1989)
J. Biol. Chem.
264,
9145-9148[Abstract/Free Full Text]
-
Picard, V.,
Ersdal-Badju, E.,
Lu, A.,
and Bock, S. C.
(1994)
Nucleic Acids Res.
22,
2587-2591[Abstract/Free Full Text]
-
Aiyar, A.,
and Leis, J.
(1993)
BioTechniques
14,
366-369[Medline]
[Order article via Infotrieve]
-
Sarkar, G.,
and Sommer, S. S.
(1990)
BioTechniques
8,
404-407[Medline]
[Order article via Infotrieve]
-
Belfort, M.,
and Pedersen-Lane, J.
(1984)
J. Bacteriol.
160,
371-378[Abstract/Free Full Text]
-
Moran, R. G.,
Spears, C. P.,
and Heidelberger, C.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
1456-1460[Abstract/Free Full Text]
-
Pogolotti, A. L. J.,
Danenberg, P. V.,
and Santi, D. V.
(1986)
J. Med. Chem.
29,
478-482[CrossRef][Medline]
[Order article via Infotrieve]
-
Wahba, A. J.,
and Friedkin, M.
(1961)
J. Biol. Chem.
236,
11-12
-
Scatchard, G.
(1949)
Ann. N. Y. Acad. Sci.
51,
660-672[CrossRef]
-
Suzuki, M.,
Christians, F. C.,
Kim, B.,
Skandalis, A.,
Black, M. E.,
and Loeb, L. A.
(1996)
Mol. Divers.
212,
111-118
-
Zhang, H. C.,
Cisneros, R. J.,
Deng, W. L.,
Johnson, L. F.,
and Dunlap, R. B.
(1990)
Biochem. Biophys. Res. Commun.
167,
869-875[CrossRef][Medline]
[Order article via Infotrieve]
-
Barbour, K. W.,
Hoganson, D. K.,
Berger, S. H.,
and Berger, F. G.
(1993)
Mol. Pharmacol.
42,
242-248[Abstract]
-
Bapat, A. R.,
Zarov, C.,
and Danenberg, P. V.
(1983)
J. Biol. Chem.
258,
4130-4136[Abstract/Free Full Text]
-
Berger, S. H.,
Barbour, K. W.,
and Berger, F. G.
(1988)
Mol. Pharmacol.
34,
480-484[Abstract]
-
Jastreboff, M. M.,
Kedzierska, B.,
and Rode, W.
(1983)
Biochem. Pharmacol.
32,
2259-2267[CrossRef][Medline]
[Order article via Infotrieve]
-
Houghton, P. J.,
Raman, A.,
Will, C. L.,
Dolnick, B. J.,
and Houghton, J. A.
(1992)
Cancer Res.
52,
558-565[Abstract/Free Full Text]
-
Davis, S. T.,
and Berger, S. H.
(1993)
Mol. Pharmacol.
43,
702-708[Abstract]
-
Hughey, C. T.,
Barbour, K. W.,
Berger, F. G.,
and Berger, S. H.
(1993)
Mol. Pharmacol.
44,
316-323[Abstract]
-
Washtien, W.
(1982)
Mol. Pharmacol.
21,
723-728[Abstract]
-
Berger, S. H.,
Jenh, C. H.,
Johnson, L. F.,
and Berger, F. G.
(1985)
Mol. Pharmacol.
28,
461-467[Abstract]
-
Clark, J. L.,
Berger, S. H.,
Mittelman, A.,
and Berger, F. G.
(1987)
Cancer Treat. Rep.
71,
261-265[Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al.
Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment
J. Clin. Oncol.,
April 1, 2006;
24(10):
1603 - 1611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, et al.
Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients
J. Clin. Oncol.,
December 10, 2005;
23(35):
8950 - 8958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. H. Guo, J. Choe, and L. A. Loeb
Protein tolerance to random amino acid change
PNAS,
June 22, 2004;
101(25):
9205 - 9210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Shi and G. C. Ferreira
Probing the Active Site Loop Motif of Murine Ferrochelatase by Random Mutagenesis
J. Biol. Chem.,
May 7, 2004;
279(19):
19977 - 19986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kawate, D. M. Landis, and L. A. Loeb
Distribution of Mutations in Human Thymidylate Synthase Yielding Resistance to 5-Fluorodeoxyuridine
J. Biol. Chem.,
September 20, 2002;
277(39):
36304 - 36311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gaspar, E. De Clercq, and J. Neyts
Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase
J. Virol.,
September 11, 2002;
76(20):
10530 - 10532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Landis, C. C. Heindel, and L. A. Loeb
Creation and Characterization of 5-Fluorodeoxyuridine-resistant Arg50 Loop Mutants of Human Thymidylate Synthase
Cancer Res.,
January 1, 2001;
61(2):
666 - 672.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. H. Patel and L. A. Loeb
DNA polymerase active site is highly mutable: Evolutionary consequences
PNAS,
May 9, 2000;
97(10):
5095 - 5100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Patel, J. A. Allay, J. A. Belt, and B. P. Sorrentino
Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells
Blood,
April 1, 2000;
95(7):
2356 - 2363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fantz, D. Shaw, W. Jennings, A. Forsthoefel, M. Kitchens, J. Phan, W. Minor, L. Lebioda, F. G. Berger, and H. T. Spencer
Drug-Resistant Variants of Escherichia coli Thymidylate Synthase: Effects of Substitutions at Pro-254
Mol. Pharmacol.,
February 1, 2000;
57(2):
359 - 366.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. E. Kitchens, A. M. Forsthoefel, K. W. Barbour, H. T. Spencer, and F. G. Berger
Mechanisms of Acquired Resistance to Thymidylate Synthase Inhibitors: The Role of Enzyme Stability
Mol. Pharmacol.,
November 1, 1999;
56(5):
1063 - 1070.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Phan, D. J. Steadman, S. Koli, W. C. Ding, W. Minor, R. B. Dunlap, S. H. Berger, and L. Lebioda
Structure of Human Thymidylate Synthase Suggests Advantages of Chemotherapy with Noncompetitive Inhibitors
J. Biol. Chem.,
April 20, 2001;
276(17):
14170 - 14177.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|